Capricor announced it intends to file a BLA for deramiocel for treatment of patients with DMD cardiomyopathy. Click here to ...

Alnylam Pharmaceuticals Inc. (ALNY) said that new data from the HELIOS-B Phase 3 study of vutrisiran showed that the drug attenuated ...

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Capricor Therapeutics (CAPR – Research Report). The ...

People with hypertrophic cardiomyopathy (HCM) have a greater risk of becoming severely ill from COVID-19. Furthermore, the virus has been found to significantly damage the heart muscle, causing ...

Discover BridgeBio Pharma's groundbreaking patent for treating ATTR cardiomyopathy with Compound 1, showcasing improved patient outcomes and reduced mortality rates.

Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading higher Tuesday after the company announced intent to file a ...

Purpose: The treatment options for viral myocarditis caused by coxsackievirus B are summarized. Summary: Myocarditis is a common cause of dilated cardiomyopathy. The most common causes of ...

Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population Study design intended to ...

NIH grant fuels research to find improved treatments for heart failure, aiming to advance care and enhance outcomes for ...

Capricor is planning to start an application seeking the FDA's approval of deramiocel for DMD-related heart disease.

Phoenix researcher was recently awarded a $1.9 million National Institutes of Health grant to study the molecular mechanisms of how dilated cardiomyopathy progresses to heart failure, which could ...